Abstracts Archive - Page 105 of 2425 - ACR Meeting Abstracts

Abstract Number: 1138 • ACR Convergence 2024
Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec
Mareva geslin¹, Julien Vachon², Naizhuo Zhao³, Elhadji Anassour Laouan Sidi², Sonia Jean⁴, audrey smargiassi² and Sasha Bernatsky⁵, ¹Universite de Montreal, Montreal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Institut national de santé publique du Québec, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Exposure to fine particles (PM2.5) has been associated with numerous health effects including with autoimmune rheumatic diseases (SARDs). While PM2.5 are composed of various…
Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Marta Bean¹, Brian Coburn¹, Thomas Riley², Elise Breed¹, Carlos M García-González¹, Akash Gupta¹, Jonathan Kotzin¹, Adam Mayer³, John Oghene¹, Ellen Romich⁴, Michael George¹, Rachel Dayno¹, Nora Sandorfi¹, Preethi Thomas¹ and Anupama Shahane¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Media, PA
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
Abstract Number: 1141 • ACR Convergence 2024
Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)
Teerin Liewluck¹, Ashley Santilli², Oliver Ni³, Margherita Milone², Duygu Selcen², Anahit Mehrabyan⁴, Arjun Seth⁵, Christine Hsieh⁵, Wasim Raslan⁶, Moayd Alkhalifah⁶, Raed Alenezi⁶, Stefan Nicolau⁷ and Pannathat Soontrapa⁸, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic-Rochester, Rochester, MN, ³Hennepin Healthcare, Minneapolis, MN, ⁴University of North Carolina, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL, ⁶Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, ⁷Nationwide Children’s Hospital, Columbus, OH, ⁸Siriraj Hospital, Mahidol University, Bangkok, Thailand
Background/Purpose: To describe a novel type of myositis, immune mediated megaconial myopathy (IMMM), pathologically characterized by giant mitochondria (megaconia).Methods: We reviewed the Mayo Clinic Muscle…
Abstract Number: 1156 • ACR Convergence 2024
Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Juan Schmukler², Kristin Wipfler³, Christopher G McKennan⁴, Jiaxuan Duan⁴, Kaleb Michaud⁵ and Yvonne Lee⁶, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Division of Rheumatology, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Pittsburgh, Department of Statistics, Pittsburgh, PA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Northwestern University, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is the prototypical central pain disorder that can be associated with rheumatic conditions such as rheumatoid arthritis, Sjogren’s disease and lupus. Patients…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1158 • ACR Convergence 2024
Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Sehreen Mumtaz¹, Megan Sullivan², Maximiliano Diaz Menindez³, Emily Craver⁴ and Florentina Berianu⁵, ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵mayo clinic, Ponte Vedra Beach, FL
Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
Abstract Number: 1113 • ACR Convergence 2024
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Young Min Cho¹, Alejandro Quintero Villegas², Matt Means³, Zanos Theodoros², Lara El Khoury⁴ and Galina Marder³, ¹Northwell, Glen Cove, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell, Manhasset, NY, ⁴Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: IgG4-RD presents various clinical manifestations, making it challenging to assess treatment responses. B-cell depletion agents such as Rituximab (RTX) are used in refractory cases.…
Abstract Number: 1162 • ACR Convergence 2024
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Xia Lyu¹, Patrick Gordon², Harsha Gunawardena³, Neil McHugh⁴, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Peter Lanyon⁶, James Miller⁷, Voon Ong⁸, Anthony Isaacs⁹, Chee-Seng Yee¹⁰, Caroline Cotton¹¹, Patrick Kiely¹², Eleni Stathopoulou¹³, James Taylor¹⁴, Rachel Jeffery¹⁴, Anurag Bharadwaj¹⁵, James Lilleker¹⁶, Janine Lamb¹⁷ and hector Chinoy¹⁸, and MYOPROSP consortium, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²nhs, London, United Kingdom, ³North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bath, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁷Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁸University College London, London, England, United Kingdom, ⁹Department of Rheumatology, London North West University Healthcare NHS Trust, London, United Kingdom, ¹⁰Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹¹Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, ¹²Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Department of Rheumatology, Solihull Hospital, University Hospitals of Birmingham NHS FT, Birmingham, United Kingdom, ¹⁴Department of Rheumatology, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton, United Kingdom, ¹⁵1Basildon University Hospital, Mid & South Essex NHS Foundation Trust, Rheumatology, Basildon, United Kingdom, Basildon, United Kingdom, ¹⁶Northern Care Alliance NHS Trust, Salford, United Kingdom, ¹⁷University of Manchester, UK, Manchester, United Kingdom, ¹⁸The University of Manchester, Manchester, United Kingdom
Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
Abstract Number: 1167 • ACR Convergence 2024
Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies
Andres Gaytan Garcia de Alba¹, Nancy R Mejía-Domínguez¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, María José Ostos-prado¹, Agustin Hernandez Lopez¹, Diana Gomez-martin² and Jiram Torres Ruiz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Mexico City, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: An important proportion of patients with Idiopathic inflammatory myopathies (IIM) are at risk of developing refractory disease, which predispose them to cumulate damage, treatment…
Abstract Number: 1119 • ACR Convergence 2024
Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis
Kailey Singh¹, Harrison Zucker¹, Alice Kwon², Audrey Liu³, Josephine Rini¹, Elena Katzap⁴, Sonali Narain⁵ and Galina Marder⁶, ¹Northwell Health at Northshore/Long Island Jewish, Manhasset, ²Northwell Health at Northshore/Long Island Jewish, Bayside, NY, ³Loma Linda University, Loma Linda, CA, ⁴Northwell Health, Great NY, NY, ⁵Northwell Health, Great Neck, NY, ⁶Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…
Abstract Number: 1134 • ACR Convergence 2024
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Christopher VanDeusen¹, Andres Gagete¹, Annelize Koch² and D Scott Batty Jr¹, ¹Artax Biopharma, Inc, Cambridge, MA, ²Simbec-Orion, Merthyr Tydfil, Wales, United Kingdom
Background/Purpose: Nck is a cytosolic protein that binds a domain of the T cell receptor (TCR) following TCR interaction to amplify responses from low affinity…
Abstract Number: 1075 • ACR Convergence 2024
Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach
Akhil Sood¹, Pegah Jahangiri¹, Christy Bill² and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford Health Care, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
Abstract Number: 1171 • ACR Convergence 2024
Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain
Rebecca Fillipo¹, Michael Brown², Jason Arnold², Colleen Burke³, Stephanie Danyluk², Kelley Seebeck² and Adam Goode², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Chapel Hill, NC
Background/Purpose: Low Back Pain (LBP) is highly prevalent, with up to 25% of individuals experiencing LBP each year, with as many as 32% transitioning to…
Abstract Number: 1148 • ACR Convergence 2024
Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis
Nantakarn Pongtarakulpanit¹, Tanya Chandra¹, shiri keret², Eugenia Gkiaouraki³, Vladimir Liarski¹, Dana Ascherman³, Siamak Mogahadam¹, Chester Oddis¹ and Rohit Aggarwal⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a clinician-scored instrument that measures activity and damage in the skin of Dermatomyositis (DM)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].